{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "OUST",
  "name": "Ouster, Inc.",
  "url": "https://orbyd.app/dossiers/OUST/",
  "json_url": "https://orbyd.app/dossiers/OUST.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a6",
    "n": 6
  },
  "current_thesis": "Squeeze leg broke: +43% in four sessions to a $63.79 high, then management priced 3.62M shares at $55.22 (~8% discount) and closed ~$191.9M net on 2026-07-06. Price round-tripped to $37.04, under the 20- and 50-day and under the $49 average target. Narrative intact, chart is not; Q2 lands 2026-08-06 with no repaired base.",
  "invalidation_trigger": "A weekly close below $33 loses the July capitulation low and confirms the June–July sequence as a distribution top, opening a retest of the rising 200-day near $28. Secondary: a Q2 print on 2026-08-06 with product revenue under the ~$49.5M low end, gross margin below the 35–40% guide, or fresh ATM issuance.",
  "catalyst_date": "2026-08-06",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-29",
  "invalidation_fired": true,
  "themes": [
    "physical-ai-robotics",
    "defense-aerospace",
    "ai-datacenter-infrastructure"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "EARNINGS: Q2 2026 confirmed for 2026-08-06 after close, call 5:00 p.m. ET (announced 2026-07-14). Blackout window opens ~2026-08-03.",
    "PRIOR $40 SHELF BROKEN: the June higher-low level that framed the last two reads failed in July. Weekly close 2026-07-17 was $37.04 after a $33.08 intraday low. Do not treat $40 as support; it is overhead supply now.",
    "~5.6% of share count. Completed 2026-07-06, ~$191.9M net. Share count now 67.29M.",
    "ATM STILL LIVE: the $100M ATM sales agreement dated 2026-05-08 sits alongside the completed offering. Supply is not exhausted.",
    "SELL-SIDE STILL RAISING INTO THE DRAWDOWN: Oppenheimer Outperform, PT $57 from $42 on 2026-07-15 with the stock in the high $30s. Consensus Strong Buy, avg PT $49.00 across 7 analysts; Roth/MKM $75, Rosenblatt $53, Cantor Neutral since 2026-05-07.",
    "MARGIN WATCH: Q1 GAAP gross margin ~43% vs ~60% prior quarter; Q2 guide only 35-40%. TTM net income -$55.83M on TTM revenue $185.33M (+57.3%).",
    "LOW-FLOAT SQUEEZE BEHAVIOUR PERSISTS: former-SPAC with meme history, repeated double-digit single sessions on press releases with no disclosed dollar value. Sizing stays probe-grade at any conviction level.",
    "REGULATORY MOAT: Rev8 BABA compliance (early July 2026) qualifies the sensors for federally funded infrastructure procurement - the channel BlueCity sells into (40+ NJ highway sites, contracted base reported >700 sites)."
  ],
  "body_markdown": "## Current Thesis\nThe second parabolic leg ran, and then the company sold into it. On 2026-07-02 management priced a 3,621,876-share underwritten offering at $55.22 — an ~8% discount to the $60.02 prior close — closing 2026-07-06 for ~$191.9M net. The tape has since given the entire move back: $37.04 on 2026-07-17, about 42% under the high, below both the 20-day (~$46.40 as of 2026-07-10) and the 50-day, and now trading beneath the $49.00 average analyst target it had spent June above. The lidar-for-Physical-AI story is intact and the balance sheet is materially stronger. The squeeze that priced it is over, and there is no repaired base yet.\n\n## Bull Case\n- **Funded, and no longer a going-concern debate.** The 2026-07-06 offering added ~$191.9M net at a price the market has not seen since. For an unprofitable sensor manufacturer scaling a contract-manufacturing ramp, buying that capital at $55.22 was opportunistic execution.\n- **Revenue growth is genuine and sustained.** Q1 2026 (2026-05-05): total revenue $48.58M, +49% YoY; product revenue a record $48.23M, +55% YoY; 13 consecutive quarters of product-revenue growth. TTM revenue $185.33M, +57.3%.\n- **Regulatory moat widened.** Rev8 BABA compliance (early July 2026) opens federally funded infrastructure procurement — the exact channel BlueCity sells into, where non-compliant foreign lidar is disqualified rather than merely disfavoured.\n- **Verticals are broadening past robotaxi.** AIM Intelligent Machines (2026-06-17) puts Rev8 native-colour sensors into autonomous mining, construction and defence fleets; Benchmark (2026-06-15) supplies the volume path; BlueCity runs at 40+ New Jersey highway sites into the 2026 FIFA World Cup against a contracted base reported above 700 sites.\n- **Sell-side kept raising into the drawdown.** Oppenheimer maintained Outperform and lifted its target to $57 from $42 on 2026-07-15 — after the offering, with the stock in the high $30s. Consensus across 7 analysts is Strong Buy, average target $49.00, with Roth/MKM at $75 and Rosenblatt at $53.\n\n## Bear Case\n- **The prior structural line has already failed.** The $40 shelf that held the early-June air pocket broke in July. Price closed the week of 2026-07-17 at $37.04 after tagging $33.08 intraday, which erases the June higher low and the May breakout base in one leg.\n- **An issuer-timed top.** Pricing 5.6% of the share count at an 8% discount two days after a 52-week high is the clearest possible statement about where management thought the stock was. Share count is now 67.29M.\n- **Dilution came on top of an existing lid.** The $100M ATM sales agreement dated 2026-05-08 remains available alongside the completed offering, so supply is not exhausted.\n- **Still loss-making, still margin-pressured.** TTM net income -$55.83M. Q1 GAAP gross margin fell to ~43% from ~60% QoQ; Q2 margin guidance was only 35–40%. At a $2.49B cap the stock trades ~13.4x TTM sales against negative operating leverage.\n- trailing-90-day insider sales totalled roughly 298,409 shares / $7.37M. No open-market purchases.\n- **Q2 lands on 2026-08-06 with the tape already broken.** A guide-down into a wounded chart is a materially different setup from a guide-down into momentum.\n\n## Setup & Price Structure\n- **Price**: $37.04 close 2026-07-17 (+5.41%), $36.66 after hours; prior close $35.14; 2026-07-15 close $37.95.\n- **52-week range**: $16.40 → $63.79. Still ~2.3x off the low, ~42% off the high.\n- **Moving averages**: below the 20-day (~$46.40 on 2026-07-10) and the 50-day; well above the 200-day (~$28.09 on 2026-07-10, now rising). The gap between spot and the 200-day is the unresolved risk.\n- **Volume signature**: 4.56M shares on the 2026-07-17 bounce against a heavy distribution sequence — 2026-07-07 -10.83% to $44.44, 2026-07-10 -6.99% to $44.21, then a further slide into the $33 handle. Down days carried the weight.\n- **Level map**: $33.08 is the July capitulation low and the first reference. $40 is now overhead resistance rather than support. $44–46 is the offering-aftermath supply shelf and the 20-day. $55.22 is the offering print, where a large tranche of new holders sits underwater.\n- **Character**: low-float former-SPAC with meme history, capable of ±16% single sessions on undated press releases. Position sizing on this name belongs in probe territory regardless of conviction.\n\n## Catalyst Calendar (next 30 days)\n\n- **Late July 2026 (est.)** — bi-monthly short-interest settlement update; relevant given the squeeze mechanics that drove the early-July leg.\n- **Ongoing, undated** — Rev8 design-win and BABA-channel infrastructure announcements. These have produced double-digit single-day moves twice in two months and remain the swing factor between prints.\n- No FDA/regulatory or index-rebalance events dated in the window.\n\n## Elapsed catalysts\n\n- **2026-08-06 (confirmed)** — Q2 2026 results after the close, call 5:00 p.m. ET. The first fundamental print since the raise; watch product revenue against the ~$49.5M low end, gross margin against the 35–40% guide, and any updated share count. *(passed 3d ago)*\n\n## What Would Change Our Mind\n- **Constructive re-rate**: a higher low above $33 followed by a weekly close back over $46 that recovers the 20-day and the offering-aftermath shelf, ideally on a dated design win with disclosed dollar value rather than another unquantified partnership release.\n- **Q2 confirmation**: 2026-08-06 product revenue above the guide with gross margin holding the 35–40% band and no new ATM issuance disclosed would convert a broken chart into a base worth working.\n- **Structural failure**: a weekly close under $33 puts the 200-day near $28 in play and reframes the entire June–July sequence as a distribution top.\n- **Narrative failure**: a Rev8 volume-ramp delay, a Benchmark scale-back, or a lost BlueCity infrastructure contract would remove the specific proof points the July move was priced on.\n\n## Correlation Notes\n- **Lidar complex** — LAZR, INVZ, AEVA, MVIS. OUST is the revenue leader of the group and sets the tone; a sympathy bid in the loss-making peers without OUST participating usually marks the low-quality end of a squeeze.\n- **Physical-AI / robotics basket** — SERV, and autonomy sleeves inside the megacap complex. The theme carried OUST from $16 to $63; theme drawdowns transmit here with amplified beta given the float.\n- **High-beta small-cap flow** — behaves like a liquidity proxy. Rate-sensitive unprofitable growth de-risking hits this name before it hits the index.\n- **Offering-overhang cohort** — names that raised into strength in July trade with the same shape: sharp discount gap, failed bounce at the pricing level, base only after the new float turns over. That comparison set is more predictive here than the lidar peers.",
  "first_seen": "2026-04-29",
  "last_analyzed": "2026-07-19T11:06:18+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}